Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

Stefan Djordjevic, Delphine Lebon, Raphael Itzykson, Hakim Ouled-Haddou, Guillaume Jedraszak, Juliette Harbonnier, Louison Collet, Etienne Paubelle, Nicolas Duployez, Jean Pierre Marolleau, Loïc Garçon, Thomas Boyer

Blood (2023) 142 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2023-179276

Published: 2023

Journal Articles

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Hélène Kemp, Laurène Fenwarth, Delphine Lebon, Nicolas Duployez, Etienne Paubelle, Magalie Joris, Amandine Charbonnier, Lydia Montes, Claude Preudhomme, Christophe Tribouilloy, Jean Pierre Marolleau, Pierre Morel

Blood (2023) 142 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2023-190177

Published: 2023

Journal Articles

Downregulation of SLC7A11 in MDS-SF3B1 Patients Induces a High Sensitivity of Erythroid Precursors to Ferroptosis

Julien Legrand, Hakim Ouled-Haddou, Stefan Djordjevic, Thanina Bouzidi, Cathy Gomila, Loïc Garçon, Etienne Paubelle

Blood (2023) 142 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2023-185703

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Blood (2023) 142 (Supplement 1): 6471.

https://doi.org/10.1182/blood-2023-177787

Published: 2023

Journal Articles

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Laura Simon, Alexis Caulier, Celine Berthon, Thomas Boyer, Véronique Harrivel, Magalie Joris, Amandine Charbonnier, Etienne Paubelle, Isabelle Leduc, Nicolas Duployez, Christophe Roumier, Claude Preudhomme, Stéphane Morisset, Jean-Pierre Marolleau, Delphine Lebon

Blood (2022) 140 (Supplement 1): 3225–3226.

https://doi.org/10.1182/blood-2022-164840

Published: 2022

Journal Articles

Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry

Hedi Bensaber, Emmanuel Bachy, David Beauvais, Remy Dulery, Thomas Gastinne, Bruno Villemagne, Louise Roulin, Etienne Paubelle, Cristina Castilla-Llorente, Thomas Longval, Elodie Gat, Amandine Fayard, Jacques-Olivier Bay, Steven Le Gouill, Roch Houot, Romain Guieze

Blood (2022) 140 (Supplement 1): 3803–3804.

https://doi.org/10.1182/blood-2022-158807

Published: 2022

Journal Articles

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Blood (2018) 132 (Supplement 1): 1444.

https://doi.org/10.1182/blood-2018-99-112825

Published: 2018

Journal Articles

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life

Sarah Huet, Etienne Paubelle, Camille Lours, Beatrice Grange, Lucien Courtois, Kaddour Chabane, Carole Charlot, Isabelle Mosnier, Thomas Simonet, Sandrine Hayette, Isabelle Tigaud, Xavier Thomas, Gilles Salles, Fabien Subtil, Pierre Sujobert

Blood (2018) 132 (8): 865–867.

https://doi.org/10.1182/blood-2018-03-840348

Published: 2018

Includes: Supplemental data

Journal Articles

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia

Maël Heiblig, Etienne Paubelle, Adriana Plesa, Marie-Oldine Geay, Delphine Manzoni, Sophie Gazzo, Isabelle Tigaud, Evelyne Callet-Bauchu, Sarah Huet, Gilles Salles, Xavier Thomas, Sandrine Hayette, Pierre Sujobert

Blood (2017) 129 (1): 128–131.

https://doi.org/10.1182/blood-2016-09-741355

Published: 2017

Journal Articles

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Lea Herpe, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3946.

https://doi.org/10.1182/blood.V128.22.3946.3946

Published: 2016

Journal Articles

A Transcriptional- and Posttranscriptional-Based Prognostic Model in Pediatric Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Lea Herpe, Christine Ragu, PhD, Franck Mortreux, PhD, Yves Bertrand, MD PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 2870.

https://doi.org/10.1182/blood.V128.22.2870.2870

Published: 2016

Journal Articles

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Lea Herpe, Christine Ragu, PhD, Yves Bertrand, MD PhD, Franck Mortreux, PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3952.

https://doi.org/10.1182/blood.V128.22.3952.3952

Published: 2016

Journal Articles

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

Etienne Paubelle, MD PhD, Sophie Ducastelle, MD, Helene Labussiere, MD, Franck E. Nicolini, MD PhD, Fiorenza Barraco, MD, Adriana Plesa, Gilles A. Salles, Eric Wattel, MD PhD, Xavier Thomas, MD PhD

Blood (2016) 128 (22): 4003.

https://doi.org/10.1182/blood.V128.22.4003.4003

Published: 2016

Journal Articles

Prognostic Impact of ABCA3 Expression in Pediatric Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Lea Herpe, Catherine Koering, PhD, Christine Ragu, PhD, Yves Bertrand, MD PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 1694.

https://doi.org/10.1182/blood.V128.22.1694.1694

Published: 2016

Journal Articles

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Etienne Paubelle, Alice Marceau, Florence Zylbersztejn, Mickael Dussiot, Ivan Cruz Moura, PhD, Pascale Cornillet-Lefebvre, MD, Jacques Delaunay, MD, Alan K. Burnett, Sylvie Castaigne, Philippe Guardiola, MD, Norbert Ifrah, MD PhD, Hervé Dombret, Claude Preudhomme, Robert K Hills, DPhil, Olivier Hermine

Blood (2015) 126 (23): 1307.

https://doi.org/10.1182/blood.V126.23.1307.1307

Published: 2015

Journal Articles

Co-Activation of AMPK and mTORC1 Is Synthetically Lethal in Acute Myeloid Leukemia

Blood (2014) 124 (21): 616.

https://doi.org/10.1182/blood.V124.21.616.616

Published: 2014

Journal Articles

Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in β-Thalassemia

Michael Dussiot, Thiago Maciel, PhD, Aurelie Fricot, Joel Veiga, Etienne Paubelle, Emmanuel Payen, Yves Beuzard, MD, Jean-Antoine Ribeil, MD, PhD, Jean-Benoît Arlet, MD, Genevieve Courtois, PhD, Tom O Daniel, MD, PhD, Rajesh Chopra, MD, PhD, Victoria Sung, Ph.D., Olivier Hermine, MD, PhD, Ivan Cruz Moura, PhD

Blood (2012) 120 (21): 247.

https://doi.org/10.1182/blood.V120.21.247.247

Published: 2012

Journal Articles

Association of Deferasirox and Vitamin D Promotes Cell Differentiation and Improves Overall Survival in Acute Myeloid Leukemia (AML) Elderly Patients After Demethylating Agents Failure: A Retrospective Case Control Study

Etienne Paubelle, Felipe Suarez, MD, PhD, Florence Zylbersztejn, Celine Callens, PharmD PhD, Michael Dussiot, Marc Benhamou, Françoise Isnard, MD, Marie T Rubio, MD, PhD, Gandhi Damaj, Norbert C. Gorin, MD, PhD, Jean-Pierre Marolleau, MD, PhD, Ivan Cruz Moura, PhD, Olivier Hermine

Blood (2012) 120 (21): 3622.

https://doi.org/10.1182/blood.V120.21.3622.3622

Published: 2012

NARROW

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Downregulation of SLC7A11 in MDS-SF3B1 Patients Induces a High Sensitivity of Erythroid Precursors to Ferroptosis

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

A Transcriptional- and Posttranscriptional-Based Prognostic Model in Pediatric Acute Myeloid Leukemia

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

Prognostic Impact of ABCA3 Expression in Pediatric Acute Myeloid Leukemia

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Co-Activation of AMPK and mTORC1 Is Synthetically Lethal in Acute Myeloid Leukemia

Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in β-Thalassemia

Association of Deferasirox and Vitamin D Promotes Cell Differentiation and Improves Overall Survival in Acute Myeloid Leukemia (AML) Elderly Patients After Demethylating Agents Failure: A Retrospective Case Control Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only